Correlation of miR-600 with WT1 expression and its potential clinical significance in breast cancer

Aim: The study aimed to explore miR-600 and WT1 expression and its potential clinical significance in breast cancer. Materials & methods: The expression of miR-600 and WT1 in tumor and non-tumor adjacent tissues in 45 breast cancer patients as well as serum level of miR-600 in these patients and 45 healthy group were analyzed. Results: The expression level of miR-600 in tumor tissue and serum of patients was significantly lower than non-tumor adjacent tissues and serum of controls, respectively, while WT1 mRNA and protein levels were higher in tumor tissues compared with non-tumor adjacent tissues. The miR-600 expression was correlated with lymph node metastasis and clinical stage. Conclusion: The miR-600 acts as tumor suppressor and a diagnostic and prognostic biomarker in breast cancer patients.

Download Full-text

Clinical Significance of Annexin A2 Expression in Breast Cancer Patients

Cancers ◽

10.3390/cancers13010002 ◽

2020 ◽

Vol 13 (1) ◽

pp. 2

Author(s):

Lee D. Gibbs ◽

Kelsey Mansheim ◽

Sayantan Maji ◽

Rajesh Nandy ◽

Cheryl M. Lewis ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Clinical Significance ◽

Cell Lines ◽

Breast Cancer Subtypes ◽

Enzyme Linked Immunosorbent Assay ◽

Breast Cancer Patients ◽

Serum Samples ◽

Cancer Subtypes ◽

Tumor Tissues

Increasing evidence suggests that AnxA2 contributes to invasion and metastasis of breast cancer. However, the clinical significance of AnxA2 expression in breast cancer has not been reported. The expression of AnxA2 in cell lines, tumor tissues, and serum samples of breast cancer patients were analyzed by immunoblotting, immunohistochemistry, and enzyme-linked immunosorbent assay, respectively. We found that AnxA2 was significantly upregulated in tumor tissues and serum samples of breast cancer patients compared with normal controls. The high expression of serum AnxA2 was significantly associated with tumor grades and poor survival of the breast cancer patients. Based on molecular subtypes, AnxA2 expression was significantly elevated in tumor tissues and serum samples of triple-negative breast cancer (TNBC) patients compared with other breast cancer subtypes. Our analyses on breast cancer cell lines demonstrated that secretion of AnxA2 is associated with its tyrosine 23 (Tyr23) phosphorylation in cells. The expression of non-phosphomimetic mutant of AnxA2 in HCC1395 cells inhibits its secretion from cells compared to wild-type AnxA2, which further suggest that Tyr23 phosphorylation is a critical step for AnxA2 secretion from TNBC cells. Our analysis of AnxA2 phosphorylation in clinical samples further confirmed that the phosphorylation of AnxA2 at Tyr23 was high in tumor tissues of TNBC patients compared to matched adjacent non-tumorigenic breast tissues. Furthermore, we observed that the diagnostic value of serum AnxA2 was significantly high in TNBC compared with other breast cancer subtypes. These findings suggest that serum AnxA2 concentration could be a potential diagnostic biomarker for TNBC patients.

Download Full-text

Clinical significance of internal mammary lymph node metastasis for breast cancer: Analysis of 337 breast cancer patients

Surgical Oncology ◽

10.1016/j.suronc.2018.03.006 ◽

2018 ◽

Vol 27 (2) ◽

pp. 185-191 ◽

Cited By ~ 5

Author(s):

Xiao-wei Qi ◽

Jun-ze Du ◽

Peng Tang ◽

Xue Liu ◽

Qing-qing He ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Cancer Patients ◽

Clinical Significance ◽

Breast Cancer Patients ◽

Internal Mammary Lymph Node ◽

Node Metastasis ◽

Internal Mammary

Download Full-text

The clinical feature of triple-negative breast cancer in Beijing, China

10.1101/2021.08.03.21261573 ◽

2021 ◽

Author(s):

Hui Zhao ◽

Yueqing Feng ◽

Junzheng Yang

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Cancer Patients ◽

Tumor Size ◽

Tumor Thrombus ◽

Clinical Stage ◽

Brca1 Gene ◽

Clinical Feature ◽

Breast Cancer Patients ◽

Node Metastasis

Objective: To collect and analyze the clinical feature of triple-negative breast cancer (TNBC) in Beijing, to provide the information for the local oncologist to make sound treatment plans. Methods: The clinical data of 280 breast cancer patients with TNBC admitted to the oncology hospital of China Academy of Medical Sciences were collected and divided into (recurrence and metastasis) group and non-(recurrence and metastasis) group. Breast cancer patients with TNBC were classified according to age distribution, family history of breast cancer, pathological type, histological grade, clinical stage, tumor thrombus, tumor size and lymph node metastasis. and 15 BRCA1 gene SNP loci were also measured by a high throughput Mass ARRAY time-of-flight mass spectrometry biochip system and compared the expression of 15 BRCA1 gene SNP loci between (recurrence and metastasis) group and non-(recurrence and metastasis) group. χ2 test was used to analyze the difference between two groups, and P<0.05 considered statistically significant. Results: A total of 280 breast cancer patients with TNBC were enrolled in this study, median age 45 years old. There were 117 cases breast cancer patients with TNBC in (recurrence and metastasis) group, accounting for 41.79% in total breast cancer patients with TNBC and 163 cases breast cancer patients with TNBC in non-(recurrence and metastasis) group, accounting for 58.21% in total breast cancer patients with TNBC; There was no significant difference in age distribution, family history of breast cancer, pathological type and histological grade between non-(recurrence and metastasis) group and (recurrence and metastasis) group (P>0.05); but there were significant differences in clinical stage, vascular tumor thrombus, tumor size and lymph node metastasis between two groups (P<0.05); and then we compared the expression of 15 BRCA1 gene SNP loci in (recurrence and metastasis) group and non-(recurrence and metastasis) group, found that BRCA1gene rs 12516 CC loci (38.8% VS 44.4%), BRCA1gene rs 12516 TT loci (15.6% VS 10.4%), BRCA1 gene rs 16940 CC loci (15.1% VS 10.4%), BRCA1 gene rs 16940 TT loci (39.0% VS 44.8%), BRCA1 gene rs 16941 AA loci (38.1% VS 44%), BRCA1 gene rs 16941 GG loci (15.0% VS 10.3%), BRCA1 gene rs16942 AA loci (39.0% VS 44.8%), BRCA1 gene rs16942 GG loci (15.1% VS 10.4%), BRCA1gene rs799906 CC loci (15.9% VS 10.4%), BRCA1gene rs799906 TT loci (38.7% VS 44.8%), BRCA1gene rs799917 CC loci (38.7% VS 44.4%), BRCA1gene rs799917 TT loci (15.7% VS 10.4%), BRCA1gene rs1060915 CC loci (15.5% VS 10.4%), BRCA1gene rs1060915 TT loci (39.1%VS 44.8%), BRCA1gene rs1799966 AA loci (37.7% VS 44.4%), BRCA1gene rs1799966 GG loci (15.1% VS 10.4%), BRCA1 Gene rs2070833 AA loci (3.1% VS 7.0%), BRCA1 Gene rs2070833 CC loci (56.3% VS 51.3%), BRCA1gene rs3737559 GG loci(78.5% VS 84.5%), BRCA1gene rs3737559 GA loci(19.0% VS 14.6%), BRCA1gene rs8176199 AA loci (60.5% VS 64.6%), BRCA1gene rs8176318 GG loci (38.4% VS 43.4%), BRCA1gene rs8176318 TT loci (15.1% VS 10.6%), BRCA1gene rs8176323 CC loci (38.6% VS 43.9%), BRCA1gene rs8176323 GG loci (15.2% VS10.5%), BRCA1gene rs11655505 AA loci (14.9% VS 10.4%), BRCA1gene rs11655505 GG loci (39.1% VS 44.8%) had a difference at the accident rate between recurrence and metastasis group and non-(recurrence and metastasis) group, but the frequencies of genotypes in the (recurrence and metastasis) group and non-(recurrence and metastasis) group were similar, there was no statistical significant correlation between the SNP genotype of the BRCA1 gene and the recurrence and metastasis risk of TNBC (P>0.05). Conclusions: There were higher recurrence and metastasis (41.79%) in total 280 cases breast cancer patients with TNBC in Beijing area; breast cancer patients with TNBC in Beijing area had a unique clinical feature no matter at clinical stage, vascular tumor thrombus, tumor size and lymph node metastasis or the expression of 15 BRCA1 gene SNP loci, those data may provide some information for clinical staff for TBNC treatment.

Download Full-text